WB, IF-F, IF-IC
H M
Endogenous
110
Rabbit
#Q14244
9053
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Immunofluorescence (Frozen) | 1:800 |
Immunofluorescence (Immunocytochemistry) | 1:800 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human MAP7 protein. Antibodies are purified by peptide affinity chromatography.
Background
MAP7 is a member of the Microtubule-Associated Proteins (MAPs) that regulates the stability and function of the cytoskeleton in cells (1). MAP7 facilitates the transport of organelles, such as mitochondria and lysosomes, via recruitment of kinesin-1 (2). This role of MAP7 in organelle transport occurs in neuronal and non-neuronal cells, including Drosophila oocytes, and in S2 cells and mammalian muscle cells (4,5). In addition to promoting organelle transport via kinesin-1 recruitment, MAP7 also contributes to the morphogenesis of axons that is domain-specific, whereas the full-length MAP7 promotes branch maturation, N- and P- domains are responsible for branch formation, and the C-terminal kinesin-interacting domain contributes to the axonal growth (3,6). MAP7 and the paralog MAP7D1 directly interact with disheveled, an effector of the Wnt5a β-catenin-independent pathway, regulating the microtubule remodeling, cell migration, and cell adhesion in HeLa cells (7). MAP7 is considered a biomarker in a model to treat multiple sclerosis based on the tolerogenic dendritic cells induced by vitamin D3 (8).
- Ramkumar, A. et al. (2018) Dev Dyn 247, 138-155.
- Chaudhary, A.R. et al. (2019) J Biol Chem 294, 10160-71.
- Tymanskyj, S.R. et al. (2018) Elife 7, pii: e36374. doi: 10.7554/eLife.36374.
- Barlan, K. et al. (2013) Curr Biol 23, 317-22.
- Metzger, T. et al. (2012) Nature 484, 120-4.
- Hooikaas, P.J. et al. (2019) J Cell Biol 218, 1298-318.
- Kikuchi, K. et al. (2018) EMBO Rep 19, pii: e45471. doi: 10.15252/embr.201745471.
- Navarro-Barriuso, J. et al. (2019) Front Immunol 10, 1251.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IF-F: Immunofluorescence (Frozen) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.